Dr. Vinayak Prasad

At-risk Americans can be reassured that they will be covered by such approvals. At the same time, we want more evidence at the U.S. Food and Drug Administration. We want to know more about what these products are doing, especially as we enter the seventh, eighth, and ninth dose.

At-risk Americans can be reassured that they will be covered by such approvals. At the same time, we want more evidence at the U.S. Food and Drug Administration. We want to know more about what these products are doing, especially as we enter the seventh, eighth, and ninth dose.

We have launched down this multi-year campaign of booster after booster after booster, and we do not have gold standard science to support this for average risk, low risk Americans.

We have launched down this multi-year campaign of booster after booster after booster, and we do not have gold standard science to support this for average risk, low risk Americans.

At-risk Americans can be reassured that they will be covered by such approvals. At the same time, we want more evidence at the U.S. Food and Drug Administration. We want to know more about what these products are doing, especially as we enter the seventh, eighth, and ninth dose.

We have launched down this multi-year campaign of booster after booster after booster, and we do not have gold standard science to support this for average risk, low risk Americans.